Downregulation of CD44 regulates extracellular matrix degradation in human pancreatic ductal adenocarcinoma cells

Creative Commons License

Gürbüz N.

Annals of Medical Research, vol.29, no.2, pp.87-92, 2022 (Peer-Reviewed Journal)


Aim: Pancreatic ductal adenocarcinoma (PDAC) has high mortality and early stage metastatic potential.

Thus, the developing new clinical approach and metastasis blocking strategy-based drugs are

essential for cure of PDAC. In this study we aimed to investigate the effects of cell surface transmembrane

glycoprotein CD44 on the regulation of key ECM proteins, integrin β1, fibronectin and

collagen IV, in Panc-1 and MiaPaCa-2 cells.

Materials and Methods: Followed by cell viability assay using MTS, fibronectin and collagen IV

protein expression levels and integrin β1 mRNA level were analyzed in Panc-1 and MiaPaCa-2 cells

treated with 50 nM negative siRNA and CD44 siRNA for 72 h using western blot and RT-PCR, respectively.

Results: Based on our findings, the downregulation of CD44 using specific siRNA led to decrease

fibronectin and collagen IV proteins expressions, and also Integrin β1 mRNA expression in both

Panc-1 and MiaPaCa-2 cell lines.

Conclusion: CD44 siRNA based therapies have effective role to inhibit ECM degradation in PDAC

progression. CD44 is also promising target for against PDAC through inhibiting migration, invasion

and metastasis steps.